PDX Pharmaceuticals
Delivery of Next-Gen Combination and Immunotherapies on Nanotechnology Platform.
Delivery of Next-Gen Combination and Immunotherapies on Nanotechnology Platform.
PDX Pharmaceuticals is an IND-enabling stage biopharmaceutical company. We develop novel combination and immunotherapies to treat cancer by bringing complementary biological pathways together to achieve synergistic clinical benefit. Our therapeutic candidates bridge the innate and adaptive immune systems by generating profound CD8+ T cell production. Our pipelines are patented AIRISE (Augmenting Immune Responses and Inhibiting the Suppressive Environment of Tumors) and ARAC (Antigen Release Agent and Checkpoint Inhibitor) pipelines that generate anti-tumor immunity when given locally (AIRISE) or systemically (ARAC) by relying on patient' s own tumor in situ as the source of antigens.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $1.55M | 1 |
|
27 Nov 2019 |
We care about your data, and we'd love to use cookies make your experience better.
